VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the successful closing of its previously announced public offering (the "Offering") of 7,607,145 common shares of the Company (the “Common Shares"), whi ...

Core Viewpoint - Eupraxia Pharmaceuticals Inc. has announced a public offering of common shares and pre-funded warrants, aiming to raise approximately US$55 million to advance its clinical programs and expand its pipeline [1][3]. Group 1: Offering Details - The public offering consists of 6,428,574 common shares priced at US$7.00 each and pre-funded warrants to purchase up to 1,428,571 common shares at US$6.99999 each, resulting in gross proceeds of about US$55 million before expenses [1]. - The offering is expected to close on February 20, 2026, pending customary closing conditions, including the listing of shares on the TSX and Nasdaq [1]. - Underwriters have a 30-day option to purchase an additional 1,178,571 common shares under the same terms [1]. Group 2: Use of Proceeds - The net proceeds will primarily fund the advancement of EP-104GI for Eosinophilic Esophagitis, including ongoing preclinical studies and Phase 2 clinical trials, as well as preparations for a Phase 3 trial [3]. - A portion of the funds will be allocated to expand clinical studies for EP-104GI in additional gastrointestinal indications and to support research and development of other pipeline candidates [3]. - The proceeds may also be used for general corporate purposes, including employee salaries, working capital, and expanding the intellectual property portfolio [3]. Group 3: Company Overview - Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products targeting high unmet medical needs [7]. - The company utilizes its proprietary Diffusphere™ technology for optimized local drug delivery [7].

VICTORIA, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the Company has filed a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated February 5, 2024 (the “Base P ...

Core Insights - Eupraxia Pharmaceuticals announced positive results from the RESOLVE trial, showing significant improvements in tissue health and symptom management for patients with eosinophilic esophagitis (EoE) after treatment with EP-104GI [1][2] Group 1: Clinical Trial Results - The RESOLVE trial is a Phase 1b/2a study evaluating EP-104GI, which has shown compelling evidence of addressing the underlying pathology of EoE at the tissue level [2][9] - At week 12, patients receiving the highest dose of EP-104GI demonstrated a near-complete normalization of tissue health, with an EoEHSS Grade improvement of -0.57 (94% improvement) and Stage improvement of -0.63 (97% improvement) [6] - Clinical remission was achieved by 58% of patients at week 12, 79% at week 24, and 67% at week 52, indicating sustained efficacy [7] Group 2: Safety and Tolerability - Over 200 patient-months of follow-up have been reported with no serious adverse events (SAEs) and no cases of oral candidiasis, indicating a favorable safety profile for EP-104GI [5][15] - The treatment has been well tolerated across all dose levels, including the highest dose of 8mg/site [15] Group 3: Future Developments - Eupraxia plans to disclose additional data from the RESOLVE trial in the coming months, with the Phase 2b part of the trial currently recruiting participants [9][10] - The top-line data from the Phase 2b trial is expected in Q3 2026, which will further assess the efficacy and safety of EP-104GI [10]

Core Viewpoint - Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) is recognized as a promising investment opportunity with analysts projecting over 77% upside potential following positive results from its Phase 2b RESOLVE trial for eosinophilic esophagitis [1] Group 1: Clinical Trial Results - The 52-week follow-up data from the RESOLVE trial indicated that all patients in Cohort 6 maintained symptom improvement at week 52, with an average reduction in SDI scores of -3.7, representing a 58% decrease [2] - Management highlighted that patients who completed 52 weeks in the trial experienced durable symptom relief, which is considered clinically meaningful [2] Group 2: Analyst Ratings and Price Target - Following the trial results, Kristen Kluska from Cantor Fitzgerald reaffirmed a Buy rating on Eupraxia Pharmaceuticals Inc. with a price target of C$15.38, indicating more than 76% upside from the current price level [3] - Eupraxia Pharmaceuticals is focused on developing locally delivered, extended-release drug products utilizing its proprietary DiffuSphere technology [3]

Core Viewpoint - Eupraxia Pharmaceuticals Inc. (EPRX) shows potential for significant upside, with a mean price target of $11.1 indicating a 75.1% increase from its current price of $6.34 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $2.47, suggesting variability in analyst predictions. The lowest estimate is $6.58 (3.8% increase), while the highest is $14.00 (120.8% increase) [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about EPRX's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, two EPS estimates have increased while one has decreased, leading to a 16.1% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - EPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While the consensus price target may not be a reliable measure of potential gains, it does provide a useful guide for price movement direction [14]

Core Insights - Eupraxia Pharmaceuticals announced positive 52-week follow-up data from its Phase 1b/2a RESOLVE trial for EP-104GI, a treatment for eosinophilic esophagitis (EoE), highlighting its potential as a once-a-year treatment option [1][2] Group 1: Trial Results - Cohorts 5 and 6 are the only groups to have reached 52 weeks in the RESOLVE trial, showing durable clinical symptom responses [3] - In Cohort 6, 2 out of 3 patients achieved clinical remission 52 weeks post-treatment, while 4 out of 6 patients from both Cohorts 5 and 6 remained in clinical remission [3] - At week 36, 67% of patients measured were in clinical remission, with no serious adverse events reported across over 200 patient-months of follow-up [3][4] Group 2: Symptom Improvement - In Cohort 6, patients experienced an average reduction in the Straumann Dysphagia Index (SDI) scores of -3.7, equating to a 58% improvement at week 52 [4] - Across Cohorts 5-7, the average reduction in SDI scores was -3.0, or 53%, at week 36, while 79% of patients in Cohorts 4-8 were in clinical remission at week 24 [4] Group 3: Pharmacokinetics - Plasma levels of fluticasone in Cohort 6 remained stable and predictable over 52 weeks, significantly lower than levels typically seen with daily asthma inhalers [4] - No serious adverse events or cases of oral or gastrointestinal candidiasis were reported during the trial [4] Group 4: Future Developments - The Phase 2b part of the RESOLVE trial is currently recruiting participants, with top-line data expected in Q3 2026 [8] - Eupraxia plans to disclose additional data from the ongoing RESOLVE trial in the coming months [7]

Core Insights - Eupraxia Pharmaceuticals reported durable symptom and tissue responses for EP-104GI, with data observed up to 52 weeks following a single treatment, indicating its potential as an effective treatment for eosinophilic esophagitis (EoE) [1][2] - The company completed a public offering raising $80.5 million, which will support the advancement of the EP-104GI program and other pipeline developments [4][2] - The company has sufficient cash reserves to fund operations and pipeline development into the first half of 2028, with cash on hand reported at $89.0 million as of September 30, 2025 [6][7] Clinical Trial Updates - The Phase 1b/2a RESOLVE Trial showed that two-thirds of patients in Cohort 5 remained in clinical remission after treatment with EP-104GI, demonstrating long-term disease control [3] - The highest-dose cohort in the RESOLVE trial exhibited the largest improvements in tissue health outcomes and eosinophil reduction, with no additional safety concerns reported [2] Financial Performance - For Q3 2025, the company incurred a net loss of $6.4 million, slightly higher than the $6.0 million loss in Q3 2024, primarily due to increased research and development costs [5] - The company’s cash position improved significantly from $33.1 million at the end of Q4 2024 to $89.0 million as of September 30, 2025, allowing for continued funding of clinical trials and operational needs [6] Market and Operational Considerations - The company is monitoring the potential impacts of proposed tariffs on Canadian goods by the U.S. government and retaliatory tariffs by Canada, which could affect its operations [8][10] - Eupraxia manufactures its clinical supplies in the U.S. and maintains U.S. dollar balances to mitigate the impact of exchange rate fluctuations [9]

Financial Performance - Total assets increased to $92.35 million as of September 30, 2025, compared to $34.94 million at December 31, 2024, representing a growth of 164%[3] - Cash reserves rose significantly to $88.96 million from $33.10 million, marking an increase of 168%[3] - The net loss for the three months ended September 30, 2025, was $6.37 million, compared to a loss of $5.99 million in the same period of 2024, representing an increase in loss of 6%[5] - The company reported a comprehensive loss of $6.88 million for the three months ended September 30, 2025, compared to a loss of $5.87 million in the same period of 2024, an increase of 17%[5] - For the nine months ended September 30, 2025, the net loss was $21,884,316, compared to a net loss of $18,212,147 for the same period in 2024, indicating an increase in losses of approximately 14.7%[12] - Loss attributable to the Owners of the Company for the three months ended September 30, 2025, was $6,361,367, compared to $5,943,325 for the same period in 2024, reflecting an increase of 7%[65] - The company reported interest income of $180,185 for the three months ended September 30, 2025, down from $304,342 in the same period of 2024, a decrease of 40.7%[73] - The company received interest of $763,107 during the nine months ended September 30, 2025, compared to $941,898 in 2024, reflecting a decrease of 19.0%[84] Expenses - Total expenses for the three months ended September 30, 2025, were $6.88 million, up from $6.27 million in the same period of 2024, reflecting an increase of 10%[5] - Research and development expenses for the nine months ended September 30, 2025, totaled $13.46 million, compared to $12.20 million in 2024, indicating a rise of 10%[5] - Total general and administrative expenses for the nine months ended September 30, 2025, were $8,807,256, up from $7,324,505 in 2024, representing a 20% increase[66] - The company incurred share issuance costs of $1,501,564, which is 6% of the gross proceeds raised under the offering in 2024[46] - The company incurred a cash used in operating activities of $18,824,881 for the nine months ended September 30, 2025, a decrease from $24,022,161 in the prior year[12] Assets and Liabilities - Shareholders' equity increased to $88.44 million as of September 30, 2025, from $31.84 million at December 31, 2024, a growth of 177%[3] - Total current liabilities increased to $3.81 million as of September 30, 2025, from $3.10 million at December 31, 2024, an increase of 22%[3] - Total accounts payable and accrued liabilities reached $3,734,890 as of September 30, 2025, up from $3,031,527 as of December 31, 2024, marking an increase of about 23.2%[30] - The company had current liabilities of $3,811,026 as of September 30, 2025, compared to $3,103,386 in 2024, which is a 22.8% increase[75] - As of September 30, 2025, the accumulated deficit reached $152,868,722, reflecting the ongoing financial challenges faced by the company[18] Cash Position - Cash and cash equivalents at the end of the period were $88,959,281, a significant increase from $8,661,796 at the end of September 2024[12] - Cash as of September 30, 2025, was $88,959,281, significantly higher than $33,101,294 in 2024, reflecting a 168.5% increase[75] - The company held cash of $83,519,651 denominated in US dollars as of September 30, 2025, compared to $3,740,799 in 2024, representing a 2231.5% increase[79] Funding and Financing - The company raised net proceeds of $73,891,109 through a public offering of 14,636,363 common shares on September 24, 2025, enhancing its cash position[19] - A new CDN$12 million convertible debt facility was established on August 1, 2024, with a maturity of 24 months, extendable by 12 months at the lenders' option[43] - The company raised $31,997,837 (CDN$44,528,190) from the issuance of 8,905,638 convertible preferred shares at a price of CDN$5.00 on October 31, 2024[49] - The company has not yet generated revenue from operations, emphasizing its reliance on external funding for continued operations[18] - The company is actively pursuing additional funding through potential partnerships and grants to support future research and development activities[19] Research and Development - The company has not generated revenue and assesses performance through the achievement of pre-clinical and clinical research goals[72] - The company recognized a depreciation expense of $44,511 for the three months ended September 30, 2025, compared to $24,908 for the same period in 2024, reflecting an increase of approximately 78.5%[27] - The company reported a total of 4,417,722 in research and development expenses for the three months ended September 30, 2025[67] - Research and development expenses for the nine months ended September 30, 2025, totaled $13,464,163, compared to $12,197,293 in 2024, indicating an increase of 10%[67] Foreign Currency and Exchange Rates - The company experienced a foreign currency translation adjustment loss of $508,633 for the three months ended September 30, 2025[5] - The company reported a foreign currency translation adjustment loss of $508,633 for the period ended September 30, 2025[10] - The impact of a 10% change in exchange rates on profit or loss would be approximately $8,242,681 for US dollar transactions as of September 30, 2025[79] Share-Based Payments - Share-based payments for the nine months ended September 30, 2025, amounted to $3,056,761, compared to $2,195,296 for the same period in 2024, representing an increase of approximately 39.3%[12] - The company recognized additional share-based payments of $112,804 due to the repricing of options on April 25, 2025[56] - The unrecognized stock-based compensation expense related to non-vested stock options was $1,780,823, expected to be recognized over a weighted-average period of 2.18 years[60] - As of September 30, 2025, the company had 5,866,155 outstanding options with a weighted average exercise price of $5.04[59] Lease and Equipment - The right-of-use asset increased to $168,760 as of September 30, 2025, from $67,023 as of December 31, 2024, representing a significant rise of approximately 151.5%[29] - The total undiscounted future minimum lease payments as of September 30, 2025, amount to $181,986, with a present value of lease liabilities of $170,603[35] - The company has entered into a lease extension for its Victoria, BC facility, with total variable lease expenses anticipated to be $81,952 for the remaining term[68] - The operating lease expense for the three months ended September 30, 2025, was $21,226, compared to $16,072 for the same period in 2024, indicating an increase of approximately 32.5%[33] Miscellaneous - The company holds 95% of the equity interest in its subsidiary, Eupraxia USA, after acquiring AMDM Holdings Inc.[63] - The company subleased approximately 616 square feet of office space, generating $7,119 in income for the three months ended September 30, 2025, compared to $6,189 for the same period in 2024[35] - The company granted a security interest in all assets, excluding patents and intellectual property, to lenders under the convertible debt facility[45]

Core Viewpoint - Eupraxia Pharmaceuticals Inc. (EPRX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is based solely on a company's changing earnings picture, tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The recent upgrade reflects an improvement in Eupraxia's earnings outlook, which is expected to lead to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Estimate Revisions - There is a strong correlation between changes in earnings estimates and near-term stock price movements, making the Zacks rating system valuable for investors [5][7]. - Eupraxia's earnings estimates have been revised upward, with a 7.6% increase in the Zacks Consensus Estimate over the past three months [9]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [8]. - Eupraxia's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10][11].